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Abstract: Cutaneous melanoma is a common type of cancer in Adolescents and Young Adults
(AYAs, 15–39 years of age). However, AYAs are underrepresented in clinical trials investigating new
therapies and the outcomes from these therapies for AYAs are therefore unclear. Using prospectively
collected nation-wide data from the Dutch Melanoma Treatment Registry (DMTR), we compared
baseline characteristics, mutational profiles, treatment strategies, grade 3–4 adverse events (AEs),
responses and outcomes in AYAs (n = 210) and older adults (n = 3775) who were diagnosed with
advanced melanoma between July 2013 and July 2018. Compared to older adults, AYAs were more
frequently female (51% versus 40%, p = 0.001), and had a better Eastern Cooperative Oncology Group
performance status (ECOG 0 in 54% versus 45%, p = 0.004). BRAF and NRAS mutations were age
dependent, with more BRAF V600 mutations in AYAs (68% versus 46%) and more NRAS mutations in
older adults (13% versus 21%), p < 0.001. This finding translated in distinct first-line treatment patterns,
where AYAs received more initial targeted therapy. Overall, grade 3–4 AE percentages following
first-line systemic treatment were similar for AYAs and older adults; anti-PD-1 (7% versus 14%,
p = 0.25), anti-CTLA-4 (16% versus 33%, p = 0.12), anti-PD-1 + anti-CTLA-4 (67% versus 56%, p = 0.34)
and BRAF/MEK-inhibition (14% versus 23%, p = 0.06). Following anti-CTLA-4 treatment, no AYAs
experienced a grade 3–4 colitis, while 17% of the older adults did (p = 0.046). There was no difference
in response to treatment between AYAs and older adults. The longer overall survival observed in
AYAs (hazard ratio (HR) 0.7; 95% CI 0.6–0.8) was explained by the increased cumulative incidence of
non-melanoma related deaths in older adults (sub-distribution HR 2.8; 95% CI 1.5–4.9), calculated by
competing risk analysis. The results of our national cohort study show that baseline characteristics
and mutational profiles differ between AYAs and older adults with advanced melanoma, leading to
different treatment choices made in daily practice. Once treatment is initiated, AYAs and older adults
show similar tumor responses and melanoma-specific survival.
Keywords: advanced melanoma; adolescents; young adults; AYA; BRAF mutation; checkpoint
inhibitors; targeted therapy; prospective nation-wide data; outcome research; clinical audit
1. Introduction
Over the past decade, various systemic treatment options have become available for patients
with advanced melanoma. These therapies include; antibodies targeting immune checkpoint
T-lymphocyte-associated protein 4 (anti-CTLA-4), programmed cell death protein 1 (anti-PD-1)
and targeted therapy against the BRAF kinases and MEK. In the Adolescent and Young Adult (AYA)
population, defined as anyone between the ages of 15 and 39 years old, melanoma is less common
when compared to adults older than 40 years of age. The 1-year incidence age-standardized risk for
older adults in the Netherlands was 68.1 per 100,000 persons in 2018, when compared to 10.3 for AYAs.
The same difference in 1-year incidence could be observed on a global scale; 8.7 per 100,000 persons
in older adults versus 0.89 in AYAs [1]. Melanoma remains, however, one of the most frequently
occurring cancers in AYAs, accounting for 4% of all cancers diagnosed in this age group [2].
Even though melanoma accounts for an important fraction of disease in AYAs, it is relatively
uncommon in this age group when looking at the whole population. Therefore, only few patients are
included in phase 3 studies. Current knowledge on prognostic factors and treatment strategies for
(advanced) melanoma patients derives from these large phase 3 trials in patients with a median age
varying between 53 and 62 [3–8] years of age. The relevance of the results from these trials for AYAs is
therefore unclear. Over the past years, multiple differences in melanoma characteristics between the
AYAs and (older) adults have been suggested.
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Daryanani et al. demonstrated that adolescents, defined as patients between 12 and 19 years
of age, more often have locally advanced superficial spreading melanoma (SSM) as compared
to adults. On the other hand, adults are more frequently diagnosed with nodular melanoma (NM) [9].
Indini et al. showed that melanoma was more common in male patients above 39 years of age,
whereas females were more commonly afflicted with melanoma when under 39 years of age [10].
Mutations in genes encoding BRAF and NRAS proteins are the most common mutations found in
melanoma, where approximately 50% of melanomas harbor a BRAF mutation and about 20% carry an
NRAS mutation [11]. One of the most striking findings in smaller retrospective studies is that a higher
incidence of BRAF mutations was observed in AYAs as compared to older adults [12], whereas NRAS
mutations are more frequently detected in adults [13]. Differences in mutational profile and extent and
manner of dissemination could influence the treatment choices made in daily clinical practice in AYAs
versus older adults. Data on initiated treatments, efficacy and survival are currently lacking.
Using prospectively collected real-life nation-wide data from the Dutch Melanoma Treatment
Registry (DMTR), we had a unique opportunity to study this specific group in a large dataset.
Our aim was to validate the previously described differences and similarities between melanomas
that are detected in AYAs versus older patients of ≥40 years of age. First, we compared baseline
characteristics of AYAs and older adults. Second, we compared treatment strategies, treatment-related
AEs and progression-free survival (PFS). Additionally, we performed a competing risk analysis for
non-melanoma-related death, next to overall survival (OS) and disease-specific survival (DSS) analyses.
2. Results
2.1. Patient Selection and Baseline Characteristics
Between July 2013 and July 2018, 4367 patients were registered in the DMTR database. In total,
3985 advanced melanoma patients were eligible for analysis; 210 between 15 and 39 years of age (AYAs)
(5%) versus 3775 older adult patients (95%). For details on patient selection, see Figure 1.
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Table 1. Clinical and tumor characteristics of AYAs and older adult with advanced melanoma, and their
primary melanomas. Eastern Cooperative Oncology Group (ECOG), lactate dehydrogenase (LDH),
metastatic stage (M-stage).
Characteristic AYA Older adult p-Value
Patients; n 210 3775
Median age, year (range) 34 (15–39) 65 (40–97)
Gender; n (%) 0.001
Male 102 (48.6) 2261 (59.9)
Female 108 (51.4) 1514 (40.1)
ECOG PS; n (%) 0.004
0 114 (54.3) 1694 (44.9)
1 46 (21.9) 1090 (28.9)
≥2 17 (8.1) 513 (13.6)
Unknown 33 (15.7) 477 (12.6)
LDH; n (%) 0.72
Normal 124 (59.0) 2171 (57.5)
Elevated (<2xULN) 40 (19.0) 817 (21.6)
High (≥2xULN) 30 (14.3) 472 (12.5)
Unknown 16 (7.6) 315 (8.3)
Metastasis in ≥3 organ sites; n (%) 68 (32.4) 1239 (32.8) 0.90
M-stage; n (%) 0.28
M1a 22 (10.5) 444 (11.8)
M1b 15 (7.1) 403 (10.7)
M1c 169 (80.5) 2829 (74.9)
Unknown 4 (1.9) 99 (2.6)
Brain metastasis; n (%) 60 (28.6) 1053 (27.9) 0.83
Symptomatic 42 (70.0) 715 (68.0) 0.74
Mutational profile; n (%) <0.001
BRAF V600 mutation 143 (68.1) 1721 (45.6)
BRAF V600E mutation 140 (66.7) 1466 (38.8)
BRAF V600K mutation 3 (1.4) 255 (6.8)
NRAS mutation 27 (12.9) 777 (20.6)
No BRAF V600 or NRAS 40 (19.0) 1277 (33.8)
Type of primary melanoma; n (%) 0.003
Superficial spreading 101 (48.1) 1535 (40.7)
Nodular 26 (12.4) 832 (22.0)
Other/unknown 83 (39.5) 1408 (37.3)
Location primary melanoma; n (%) 0.003
Unknown primary 49 (23.3) 571 (15.1)
Head and neck 38 (18.1) 525 (13.9)
Trunk 64 (30.5) 1433 (38.0)
Extremities 55 (26.2) 1142 (30.3)
Acral 4 (1.9) 104 (2.8)
Breslow thickness; n (%) <0.001
≤2mm 90 (42.9) 1214 (32.2)
2–4mm 43 (20.5) 943 (25.0)
>4mm 20 (9.5) 754 (20.0)
Unknown 57 (27.1) 864 (22.9)
Characteristics of the primary melanoma are shown in the lower part of Table 1. AYAs had
more SSM, while the primary was more frequently NM in older adults (p = 0.003). Furthermore,
the primary tumor location was more often unknown in AYAs (23.3% versus 15.1%) or located in the
head/neck region (18.1% versus 13.9%), while older adults had more primary melanomas on the trunk
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(38.0% versus 30.5%), p = 0.003. AYAs more often had thinner melanomas (Breslow thickness ≤2 mm)
when compared to older adults, 42.9% versus 32.2%, p < 0.001.
2.2. Tumor Mutations
As shown in Table 1, AYAs more frequently harbor a BRAF V600 mutation (68.1% versus 45.6%),
while older adults more frequently harbor an NRAS mutation (20.6% versus 12.9%) or have no BRAF
V600 nor NRAS mutation (33.8% versus 19.0%), (p < 0.001). When further analyzing the percentage
of patients having a BRAF V600 or NRAS mutation over different age groups, it was shown that the
presence of a BRAF mutation is age dependent and shows a clear decrease of mutations over the
7 age groups in Figure 2. In the youngest AYA patient group between 15 and 29 years of age, 63.8% of
patients harbored a BRAF V600 mutation, while of the patients of 80 years and older only 24.8% had
this mutation.
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Figure 2. Incidence of BRAF, NRAS and KIT mutations in different age groups. Data on Adolescents
and Young Adults (AYA) and older adults (Adult) is shown.
Furthermore, the percentage of patients with an NRAS mutation increased with age. In the
youngest patient group, 10.6% harbored an NRAS mutation, in patients of 80 years and over this
was 23.5%. Overall, the incidence of KIT mutations was low (1.2%). There seemed to be a slight
increase over age, from 0% to 1.5% in the oldest patient group.
2.3. I itial Treatment
We analyzed the first-line treatment of all patients. Treatment patterns between AYAs and older
adults differed significantly, p < 0.001. More AYAs were initially treated with BRAF/MEK-inhibition
(35.2%) versus older adults (26.6%). Although the percentage of patients treated with immune
checkpoint inhibitors did not differ between AYAs (33.8%) and older adults (37.6%), AYAs were
given combination therapy with anti-PD-1 + anti-CTLA-4 more frequently (10.0% versus 4.5%),
whereas monotherapy with anti-PD-1 was preferred in older adults (22.4% versus 14.8%), see Figure 3.
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Figure 3. First-line melanoma treatment initiated in Adolescents and Young Adults (AYA) and older
adults (Adult).
The initiation of BRAF/MEK-inhibition in AYAs remained constant over time since the start of
our registry. Once anti-PD-1 was introduced, it largely replaced anti-CTLA-4 as first-line immune
checkpoint inhibition in both AYAs and older adults. However, anti-PD-1 became more popular in
older adult , while anti-CTLA-4 + anti-PD-1 was prescribed more to AYAs, see Figure S1.
In AYAs, 42 patients (20.0%) did not receive any syste ic treatment first-line versus 1027 older
adult (27.2 ). Twenty-nine AYAs underwe t metastasectomy as fir t-line treatme t versus 385 of the
adults (69.0% versus 37.5%, p < 0.001). This difference was no longer significant after stratification for
ECOG performance status, LDH level or M-stage. There was no difference in the percentage of patients
receiving radiotherapy (33.3% versus 38.2%, p = 0.53). This treatment was given in the palliative setting
in 64.3% of the AYAs and 50.3% in older adults.
2.4. Treatment Toxicity
There was no difference in the occurrence of grade 3–4 AEs in AYAs or older adults for anti-PD-1
(6.5% versus 13.7%, p = 0.25), anti-CTLA-4 (15.8% versus 32.6%, p = 0.12) or anti-PD-1 with anti-CTLA-4
(66.7% versus 55.6%, p =0.34), nor following treatment with BRAF/MEK inhibitors (13.5% versus 22.8%,
p = 0.06), see Figure 4. Data on types of grade 3–4 AEs is provided in Table S1.
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Although colitis is one of the most frequently reported AEs following anti-CTLA-4 treatment in
large phase 3 trials, AYAs did not seem to be affected. Following initial treatment with anti-CTLA-4
none of the 19 AYAs developed a grade 3–4 colitis, while 71 (17.4%) of the older adults did, p = 0.046.
When we expanded the analysis, including all anti-CTLA-4 treated patients, regardless of the treatment
line, we found that only 1 of the 48 (2.1%) AYAs experienced a grade 3–4 colitis. When we analyzed all
older adults who received anti-CTLA-4 in any line of treatment, 134 of the 893 patients developed a
3–4 grade colitis (15.0%). Therefore, the difference in grade 3–4 colitis between AYAs and older adults
remained significant, regardless of the timing of treatment, p = 0.013.
Furthermore, AYAs more often developed a grade 3–4 hepatitis following anti-PD-1 and
anti-CTLA-4 combination treatment when compared to older adults (9 out of 21 versus 36 out
of 169, p = 0.03). The relatively high incidence of hepatitis in AYAs was only seen in the first line
of treatment. When we analyzed all patients that were ever treated with combination checkpoint
inhibition 26.4% of AYAs and 18.0% of older adults developed a hepatitis (p = 0.14).
2.5. Response to Systemic Treatment
We compared the best overall response (BOR) and overall response rates (ORR) between
AYAs and older adults following either initial anti-PD-1, anti-CTLA-4, anti-PD-1 + anti-CTLA-4
or BRAF/MEK-inhibition, see Table 2. Although none of the treatment groups showed a difference
in ORR, there was a difference in BOR between AYAs and older adults treated with initial anti-PD-1.
AYAs more often had a complete response (CR) (38.7% versus 16.7%), while older adults had more
partial response (PR) (35.6% versus 16.1%).
Table 2. Best overall response and objective response rate following systemic treatment in Adolescents
and Young Adults (AYAs) and older adults. Best overall response (BOR) was classified as either;
progressive disease (PD), stable disease (SD), partial response (PR) or complete response (CR).
Objective response rate (ORR) was the combination of PR and CR.
Anti-PD-1 AYAs (n = 31) Older adults (n = 779) p-Value
PD 9 (29.0) 196 (25.2)
SD 5 (16.1) 176 (22.6)
PR 5 (16.1) 277 (35.6)
CR 12 (38.7) 130 (16.7)
ORR 17 (54.8) 407 (52.2) 0.78
Anti-CTLA-4 AYAs (n = 17) Older adults (n = 385)
PD 10 (58.8) 166 (43.1)
SD 5 (29.4) 143 (37.1)
PR 1 (5.9) 45 (11.7)
CR 1 (5.9) 31 (8.1)
ORR 2 (11.8) 76 (19.7) 0.42
Anti-PD-1 and anti-CTLA-4 AYAs (n = 18) Older adults (n = 146)
PD 8 (44.4) 35 (24.0)
SD 0 28 (19.2)
PR 7 (38.9) 69 (47.3)
CR 3 (16.7) 14 (9.6)
ORR 10 (55.6) 83 (56.8) 0.92
BRAF/MEK inhibitor AYAs (n = 68) Older adults (n = 923)
PD 15 (22.1) 148 (16.0)
SD 12 (17.6) 272 (29.5)
PR 36 (52.9) 452 (49.0)
CR 5 (7.4) 51 (5.5)
ORR 41 (60.3) 503 (54.5) 0.35
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2.6. Survival
There was no difference in PFS following systemic therapy in AYAs and older adults, see Figure 5.
The 1-year PFS for anti-PD-1 was 42.2% (95% CI 23.8–60.6) in AYAs and 44.1% (95% CI 40.6–47.6) in
older adults, p = 0.93. Following anti-CTLA-4 treatment, 1-year PFS of AYAs was 15.8% (95% CI 0–32.3)
and 16.7% (95% CI 12.9–20.4) for older adults, p = 0.51. The combination treatment of anti-PD-1 and
anti-CTLA-4 yielded a 1-year PFS in AYAs of 50.0% (95% CI 28.0–72.0) and 40.2% (95% CI 32.0–48.4) in
older adults, p = 0.60.Cancers 2020, 12, x 8 of 15 
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Figure 5. Progression free survival following first-line systemic therapy in Adolescents and Young
Adults (AYAs) and older adult (Adult) patients. Hazard ratio (HR) for progression is provided,
along with the adjusted HR (adjusted for: lactate dehydrogenase level, Eastern Cooperative Oncology
Group performance status, distant metastasis in ≥3 organ sites, the presence of brain metastases and
the presence of a BRAF V600 mutation).
There were lso no ifferenc s in PFS following targeted therapy: 1-year PFS in AYAs was 38.8%
(95% CI 27.2–50.4), and 35.0 (95% CI 31 9–38.1) in older adults, p = 0.58. In Figure 5, both the crude
HR for progression and djus ed HR are shown.
There was an OS advan age of AYAs over older adults, with a 1-year su vival of 64.7%
(95% CI 58.0–71.4) versus 55.0% (95% CI 53.4–56.6), p < 0.001. The HR for OS in AYAs was 0.69
(95% CI 0.57–0.84, p < 0.001) as compared to older adults (Table 3). The OS benefit of AYAs was higher
in patients without a BRAF V600 mutation. How ver, even after adjusting f r known prognostic
factors (including BRAF V600 mutation) the influence of ag group remain d significant; adjHR 0.68
(95% CI 0.56–0.83, p < 0.001).
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Table 3. Overall survival, disease specific survival and competing risk analyses of all advanced
melanoma patients.
Events (n) Crude HR Adjusted HR
AYA Adult HR 95% CI p-Value HR 95% CI p-Value
OS 102 2292 0.69 0.57–0.84 <0.001 0.68 0.56–0.83 <0.001
DSS 90 1728 0.81 0.66–1.00 0.06 0.79 0.64–0.98 0.03
Competing Risk 90 1728 0.90 * 0.73–1.11 0.32 0.92 * 0.75–1.13 0.43
Non-Melanoma
nMSS 12 574 0.32 0.18–0.57 <0.001 0.33 0.18–0.58 <0.001
Competing risk 12 574 0.36 * 0.20–0.63 <0.001 0.37 * 0.21–0.67 <0.001
Data on Cox proportional hazard model for overall survival (OS), disease specific survival (DSS), non-melanoma
specific survival (nMSS) and Fine and Gray cause-specific cumulative incidence of death (competing risk) is shown.
Number of deaths is shown (events) per age group; Adolescents and Young Adult (AYA) versus older adults
(Adult). Crude hazard ratio (HR), and adjusted HR are shown. HR were adjusted for: lactate dehydrogenase level,
Eastern Cooperative Oncology Group performance status, distant metastasis in ≥3 organ sites, brain metastases and
the presence of a BRAF V600 mutation. * Sub-distribution HR, from the Fine and Gray model.
In AYAs 88.2% of all deaths was caused by melanoma, this was 75.1% in older adults, p = 0.002.
DSS and a competing risk analysis were performed to further investigate the difference in OS between
AYAs and older adults. The DSS was better in AYAs (HR 0.81; 95% CI 0.66–1.00 and adjHR 0.79;
95% CI 0.64–0.98). The competing risk analysis showed that the difference in OS between AYAs and
adults could be explained by the occurrence of more non-melanoma-related deaths in the older patient
group. When accounting for non-melanoma related death as a competing risk, there was no difference
between AYAs and older adults; sub-distribution HR (sHR) 0.90 (95% CI 0.73–1.11), adjusted sHR 0.92
(95% CI 0.75–1.13).
When addressing the non-melanoma-related deaths, both the non-melanoma specific survival
(nMSS) and the sHR for melanoma specific death in AYAs as compared to older adults were lower.
This indicated that AYAs had a significantly lower HR and sHR of dying of a non-melanoma-related
cause; HR 0.32 (95% CI 0.18–0.57) and adjHR 0.33 (95% CI 0.18–0.58), sHR 0.36 (95% CI 0.20–0.63) and
adjusted sHR 0.37 (95% CI 0.21–0.67). In Table 3 both the crude and adjusted HR for survival of AYAs
and older adults is shown.
3. Discussion
In the largest prospective cohort study thus far, we observed that on a nation-wide scale 5% of all
advanced melanoma patients were AYAs. Furthermore, we showed that BRAF and NRAS mutations
are age dependent, leading to more AYAs being treated with targeted therapy. As current treatment
strategies for this age group are adapted from clinical trials that mostly include older adults, it is
important to investigate advanced melanoma in this young patient group [3,4].
By studying baseline characteristics of AYAs and older adults, we found more female patients
in the AYA group than in the older adult group. This could be explained by both biological gender
differences [14,15] and behavior differences between male and female patients. Donley et al. recently
suggested that an early age at menarche and a late age at menopause are associated with an increased
risk of melanoma in postmenopausal women [16]. An earlier study by Smith et al. and a recent study
by Støer et al., however, did not find convincing evidence that reproductive factors are associated with
an increased risk of melanoma [17,18]. As a result that the women in these studies had a median age
of 53.5 (Smith et al.) and 48 years (Støer et al.), future research might focus on reproductive factors
and exogenous estrogen use in younger women to try to explain why advanced melanoma is more
abundant in women than in men within AYAs, when compared to older adults.
We determined a significant difference in the distribution of histological subtype of melanoma
between the two age groups of interest. AYAs more often presented with SSM as compared to older
adults, whereas older adults more frequently presented with NM. This is in accordance to what
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Verzì et al., Bartenstein et al. and Daryanani et al., previously described, although in cohorts with
younger patients [9,19,20]. Moreover, we found that AYAs had significantly thinner tumors than older
adults. Relatively more AYAs had a tumor with a Breslow depth below 2 mm, suggesting that these
tumors were nevertheless more aggressive as they did develop into advanced disease. From earlier
research we know that melanomas of patients under the age of 20 years were significantly thicker
than the melanomas seen in their adult control group [21]. This difference could be explained by the
relatively small number of patients under 20 years of age in our AYA group (n = 6).
Our analysis of mutational profiles revealed that the frequency of a BRAF V600 mutation declines
with age, whereas the frequency of an NRAS mutation increases with age. Our findings support
previous studies that found BRAF mutations to be more abundant in the AYAs than in older adults.
A possible explanation is that melanomas without BRAF mutations require accumulation of high UV
doses over time, further supported by the difference in anatomic site of primary tumor [13,22].
Moreover, AYAs were treated significantly more often with combination therapy (anti-CTLA-4
+ anti-PD-1) than older adults. These differences might be explained by less fear of AEs in AYAs.
However, we did not find differences in occurrence of grade 3–4 AEs between AYAs and older adults
following immune checkpoint inhibition or BRAF/MEK-inhibition.
Interestingly, there was a difference in toxicity pattern following anti-CTLA-4 monotherapy and
in combination with anti-PD-1. Following combination treatment, more AYAs developed a hepatitis
when compared to older adults (9 out of 21 versus 36 out of 169). None of the 19 AYAs developed a
colitis following initial anti-CTLA-4 monotherapy, while 71 out of 408 older adults did. It has been
suggested that the gut microbiota can influence the occurrence of treatment-related AEs and even
treatment efficacy after checkpoint inhibitor therapy [23]. The Bacteroidetes phylum of the intestinal
microbiota has been identified to be protective against anti-CTLA-4-induced colitis by stimulating
the differentiation of regulatory T-cells, thereby limiting inflammation [24]. The intestinal microbiota
changes throughout the human lifetime. It is unclear, however, whether AYAs have a higher proportion
of Bacteroidetes than older adults, as recent studies have shown contradicting results [25,26]. Based on
our findings, we encourage researchers of the intestinal microbiota to incorporate age dependent
differences in their results.
Increased age is associated with changes in host immunity that could impact the effectiveness of
checkpoint inhibition. With advancing age, the immune system remodels and declines, predisposing
older adults and elderly to a higher risk of infections, auto-immune diseases and malignancies as
compared to younger adults [27]. The naïve T-cell compartment declines 2-5-fold between the ages of
30 and 70 years old, and the ability to establish immunological memory to newly introduced antigens
is compromised [28,29]. Furthermore, it was shown that CD4+ T-cells of patients ≤ 50 show more
signs of activation, when compared to patients ≥ 65 years of age [30]. These factors can contribute to a
less effective T-cell immune response against melanoma cells after immunotherapy with checkpoint
inhibition in older adults and elderly as compared to the younger population. However, we established
that there was no difference in response, nor PFS between AYAs and older adults following immune
checkpoint inhibition or targeted therapy. In addition, we showed that the favorable OS of AYAs as
compared to older adults is due to an increased risk for adults to die from a non-melanoma-related cause.
Strengths of our dataset include the fact that all data are prospectively registered by trained
data managers and is subsequently approved by the treating physician. Moreover, our analysis is
based on nation-wide data. However, there are some limitations. During data collection treatment
patterns for patients with advanced melanoma have changed. In the early stages of the DMTR dataset,
tumor mutational status was not determined in all patients. Additionally, we might not have included
all patients between 15 and 18 years of age, as some might not have been referred to the medical
oncologist. Furthermore, we relied on data registered in the DMTR database, which was mostly of
clinical origin. It would be interesting to combine the clinical results with data on immunological
parameters in both the blood, tumor and stroma. Additionally, we did not have supplementary
information on specific mutation signatures or whole genome sequencing data to compare AYAs
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with older adults. In accordance with our current data, both Krauthammer and Wilmott report
a high frequency of BRAF mutations in younger patients, while adults more frequently harbor
NRAS mutations. Furthermore, Krauthammer et al. showed that the presence of NF1 and RASA2
mutations was also age dependent. The presence of NF1 mutations was associated with a UV-derived
mutation signature, higher mutational load and lower disease-specific survival [31]. The article by
Willmott et al. published whole genome sequencing data from 25 Australian AYA and 121 adult
patients [13]. They found high mutational signatures of ultraviolet radiation damage in all patients.
It would be interesting to compare whole genome sequencing data from AYAs and older adults from the
Netherlands, or another non-high ambient ultraviolet radiation country, with the data from Australia.
This could shed more light on the reasons why AYAs develop advanced melanoma at a younger age,
and which (distinct) signaling pathways are used.
4. Materials and Methods
4.1. Data Source
Advanced melanoma patients in the Netherlands, irrespective of the type of primary melanoma,
are registered in the DMTR following referral to one of the 14 expert hospitals in the Netherlands.
The nation-wide centralization of advanced melanoma patients and their registration in the DMTR was
initiated in 2012 to assure safety and quality of melanoma care [32]. Up till May 2018, patients between
15 and 18 years of age were mostly treated at the previously mentioned 14 expert hospitals. Since then,
all children <18 years of age are referred to the department of Pediatric Oncology at the Princess
Máxima Center. Information on patient and tumor characteristics, treatment regimens, grade 3–4
AEs (according to the Common Terminology Criteria for Adverse Events, version 4.0) and clinical
outcomes have since been entered into the DMTR. Data are collected from patient files by trained data
managers and approved by the treating physicians. The study was conducted in accordance with the
Declaration of Helsinki. In compliance with Dutch regulations, the DMTR was approved by a medical
ethical committee (METC Leiden University Medical Center, 2013) and is not considered subject to the
Medical Research Involving Human Subjects Act.
4.2. Patients
Between July 2013 and July 2018, 4367 patients with advanced melanoma were registered in the
DMTR, follow-up data cut-off was set at March 1st, 2019. The patients with missing data on gender
(n = 1) and patients under the age of 15 years old (n = 6) were excluded from the analysis. Furthermore,
patients with mucosal and uveal melanoma were excluded from analysis (n = 375). After including
all eligible patients, 3985 patients were analyzed according to their age at registration of advanced
melanoma. Treatment strategies were categorized as systemic therapy and non-systemic treatment.
Systemic therapy was further subdivided into chemotherapy (Dacarbazine/DTIC), immune checkpoint
inhibition (anti-CTLA-4, anti-PD-1 or a combination of both), targeted therapy (BRAF-inhibition with or
without MEK-inhibition) and ‘’other” systemic therapy. Treatment strategies could have been initiated
either as standard care or in the context of participation in a clinical trial. Non-systemic treatment
was further subdivided into metastasectomy (systemic therapy ‘’no”, surgery ‘’yes” and metastatic
lesion identified) and radiotherapy (palliative yes versus no). Differences in treatment pattern between
AYAs and older adults were assessed using a Pearson’s chi-square test. In adherence with international
guidelines and literature, AYAs were defined as all patients between 15 and 39 years of age [33].
4.3. Statistical Analysis
Patients were classified according to age group for all analyses; AYAs versus older adults.
Patient baseline characteristics, type of primary tumor, localization of metastases (based on TNM 7th
edition [34]), number of organ sites involved and frequencies of systemic therapy administration were
determined using descriptive statistics. The difference between categorical variables for the different
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age groups was tested with a Pearson’s chi-square test. A median test for independent medians tests
was used to compare the time from primary diagnosis until advanced disease.
A univariable Cox analysis using the variables “gender” (male versus female),
“ECOG performance status” (ECOG 0, ECOG 1 or ECOG 2), “LDH level” (not elevated, elevated within
2× upper limit of normal or strongly elevated >2× upper limit of normal), “brain metastases”
(yes versus no), “distant metastasis in ≥3 organ sites” (yes versus no), “histologic type of melanoma”
(superficial spreading versus nodular and versus other), “location primary tumor” (unknown primary,
head-and-neck region, trunk, extremities or acral) and “BRAF mutation” (whether a BRAFV600E
or BRAFV600K mutation was present versus absent) was performed. Subsequently, a multivariable
Cox regression model was estimated, including the following prognostic factors; LDH level,
ECOG performance status, distant metastasis in ≥3 organ sites, the presence of brain metastases,
BRAF mutation [35–37]. The histologic subtype of primary melanoma (specifically superficial
spreading and nodular) was not added to the multivariable analysis as the prognostic value in the
advanced setting seems limited. A recent study showed no difference in survival between these
subtypes following immune checkpoint inhibition. Nodular melanoma had a worse prognosis
following targeted therapy. However, LDH level, ECOG performance status and number of metastases
were not added in their multivariate analysis [38].
To compare the safety of initial systemic treatment between AYAs and older adults, all included
patients received at least one infusion/treatment with anti-CTLA-4, anti-PD-1, anti-CTLA-4 and anti-PD1
or BRAF/MEK inhibition. Differences in grade 3–4 toxicity were tested with a Pearson’s chi-square test.
Response evaluation in this uncontrolled real-world setting was based on clinical judgement of
the medical team and was partially based on the RECIST 1.1 criteria. The BOR is the best evaluation
that a patient received after initiation of treatment, until the start of a new melanoma therapy, or last
visit at the treating physician; CR, PR, SD or PD. The ORR is defined by clinicians as having CR and PR.
Differences in ORR between AYAs and older adult patients was tested with a Pearson’s chi-square test.
Due to the limited number of AYAs in the different response groups, no test was performed to assess
the possible statistical difference in BOR.
OS, PFS and DSS were used to estimate survival probabilities [39]. As it is known that younger
patients have a longer life expectancy, we used the cumulative incidence competing risk method
(CIRC) to estimate melanoma-related mortality risk. To estimate survival, cumulative incidence curves
with non-melanoma-related death as competing risk were used. To estimate sHR and corresponding
95% CI, Fine and Gray competing risk models were used with melanoma-related death as event and
non-melanoma-related death as competing risk. Follow-up started at first visit after the diagnosis of
advanced disease [40,41].
All statistical analyses were conducted using SPSS (IBM Corp. Released 2017. IBM SPSS Statistics
for Windows, Version 25.0. IBM Corp, Armonk, NY, USA) and STATA (StataCorp. 2015. Stata Statistical
Software: Release 14.1. College Station, StataCorp LP, Lakeway Drive College Station, TX, USA).
5. Conclusions
Concluding, we show, for the first time, on a nation-wide scale and with real-life data that the
frequency of a BRAF V600 mutation declines with age, whereas the frequency of an NRAS mutation
increases with age in patients with advanced melanoma. Furthermore, AYAs with advanced stage
melanoma are more commonly afflicted with the histologic subtype of superficial spreading melanoma
and have thinner tumors than older adults. Moreover, first-line treatment for AYAs is more often
BRAF/MEK-inhibition or the combination of anti-CTLA-4 + anti-PD-1. These treatments lead to similar
responses in both AYAs and older adults. Interestingly, toxicity patterns in AYAs were distinct with
regard to anti-CTLA-4 monotherapy and combination treatment with anti-PD-1. Our study is an
important step towards a better understanding of advanced melanoma in AYAs and might open doors
for new studies with AYAs in order to improve daily clinical practice for advanced melanoma in the
younger population.
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Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/8/2072/s1,
Table S1. Grade 3–4 toxicity following initial systemic treatment. Subtypes of adverse events per treatment
type are shown for Adolescents and Young Adults (AYA) and older adults (Adult). Figure S1: Types of
initial systemic treatment initiated since the diagnosis of advanced melanoma. Cumulative number of targeted
therapy and immune checkpoint inhibition initiated over time since July 2013 for Adolescents and Young Adults
(AYA, solid line) and older adults (Adult, dotted line) is shown.
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